^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    SIRPA antagonist

    Related drugs:
    6d
    A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    SIRPA (Signal Regulatory Protein Alpha)
    |
    ezabenlimab (BI 754091) • BI 765063 • BI 770371
    20d
    pH-triggered Mn-ZIF8 nanoreactor enhances tumor immunotherapy by amplifying the cGAS-STING pathway through a self-reinforcing gas-metal synergy strategy. (PubMed, J Nanobiotechnology)
    In this study, we propose a Gas-Metal Synergy Strategy, which integrates immune activation and biosafety, by engineering a pH-responsive manganese-based zeolitic imidazolate framework (named MRPH) nanoplatform co-loaded with the nitric oxide (NO) donor RRX-001...Both in vitro and in vivo studies demonstrate that MRPH significantly enhances gas-amplified metalloimmunotherapy. This work pioneers a low-toxicity paradigm that integrates gas therapy and metal-based immunotherapy, offering a transformative approach to solid tumor immunotherapy.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    nibrozetone (RRx-001)
    1m
    Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=130, Recruiting, Sairopa B.V. | N=90 --> 130 | Trial completion date: Dec 2025 --> Jul 2027 | Trial primary completion date: Dec 2025 --> May 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • ADU-1805
    1m
    TQB2928-ALTN-Ib-01: TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors (clinicaltrials.gov)
    P1, N=20, Terminated, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | N=43 --> 20 | Trial completion date: Feb 2026 --> Jun 2025 | Recruiting --> Terminated | Trial primary completion date: Oct 2025 --> Jun 2025; This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Focus V (anlotinib)
    3ms
    A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone (clinicaltrials.gov)
    P1, N=90, Recruiting, Boehringer Ingelheim | Trial completion date: Mar 2028 --> Jul 2027 | Trial primary completion date: Jul 2027 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • BI 770371
    4ms
    A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes (clinicaltrials.gov)
    P1, N=56, Terminated, Bristol-Myers Squibb | Completed --> Terminated; Business objectives have changed
    Trial termination
    |
    Venclexta (venetoclax) • azacitidine • anzurstobart (BMS-986351)
    4ms
    Dual STING activation and CD47/SIRPα blockade via chitooligosaccharide-based nanoparticles to amplify antitumor immunity. (PubMed, J Control Release)
    To further counter immune evasion, we encapsulated the CD47/SIRPα inhibitor RRX-001 into reactive oxygen species (ROS)-responsive carriers, yielding RRX@RCD...In CT26 tumor-bearing mice, RRX@RCD achieved superior tumor regression, doubled median survival. Overall, RRX@RCD synchronizes innate and adaptive immune activation, offering a safe and potent nanomedicine strategy for durable antitumor immunity.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • STING (stimulator of interferon response cGAMP interactor 1) • SIRPA (Signal Regulatory Protein Alpha)
    |
    nibrozetone (RRx-001)
    5ms
    A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH (clinicaltrials.gov)
    P2, N=28, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BI 770371
    5ms
    A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab (clinicaltrials.gov)
    P1, N=13, Recruiting, Boehringer Ingelheim | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Oct 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    SIRPA (Signal Regulatory Protein Alpha)
    |
    ezabenlimab (BI 754091) • BI 765063 • BI 770371
    5ms
    A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH (clinicaltrials.gov)
    P2, N=24, Recruiting, Boehringer Ingelheim | Active, not recruiting --> Recruiting
    Enrollment open
    |
    BI 770371
    6ms
    A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH (clinicaltrials.gov)
    P2, N=24, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BI 770371
    7ms
    Signal Transducer Nanoparticles Enable Siglec-10/G Blockade Immunotherapy for Breast Cancer Treatment. (PubMed, Adv Mater)
    The therapeutic effects can be further improved through encapsulation of RRx-001, a small molecule inhibitor of the CD47-SIRPα signaling. Compared to the antibody approach, the synthetic nanoparticle approach offers greater efficacy with lower side effects and enables combination therapy through a simple formulation. Moreover, the approach is versatile and could be adapted for targeting other ICB signaling, advancing the next generation of cancer immunotherapy.
    Journal
    |
    CD24 (CD24 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
    |
    nibrozetone (RRx-001)